Video

Urology Times 50 Innovations Series: Urinary molecular biomarkers in prostate cancer

Author(s):

Urology Times staff

“Our ability to develop innovative technologies and approaches continues to evolve. We have newer molecular profiling techniques that are being applied to urine at the moment,” says Simpa Salami, MD, MPH.

Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Simpa Salami, MD, MPH, discusses the development of urinary biomarkers in prostate cancer detection. Salami is an assistant professor of urology at the University of Michigan, Ann Arbor.

Related Videos
Daniel Kwon, MD, answers a question during a Zoom video interview
DNA helix | Image Credit: © BillionPhotos.com - stock.adobe.com
DNA molecules | Image Credit: © vitstudio - stock.adobe.com
Daniel Kwon, MD, answers a question during a Zoom video interview
Randy A. Vince Jr, MD, MS, answers a question during a Zoom video interview
Related Content
DNA helix | Image Credit: © Siarhei - stock.adobe.com
December 17th 2024

Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer

Urology Times staff
Test your knowledge of this quiz on the Canadian Urological Association's recommendations for genomic profiling of tumors in prostate cancer.
DNA molecules | Image Credit: © vitstudio - stock.adobe.com
December 10th 2024

Quiz: CUA guidelines on germline genetic testing in prostate cancer

Urology Times staff
Test your knowledge of his quiz the Canadian Urological Association's recommendations for germline genetic testing in prostate cancer management.
Epigenomic cfDNA may accurately assess PSMA expression, Lu-PSMA response in mCRPC
November 26th 2024

Epigenomic cfDNA may accurately assess PSMA expression, Lu-PSMA response in mCRPC

Hannah Clarke
“Our study highlights the potential of epigenomic profiling from a simple blood draw to provide a real-time, non-invasive readout of PSMA expression that corresponds with treatment response," says Jacob E. Berchuck, MD.
Survey sheds light on international genetic testing patterns in prostate cancer
November 18th 2024

Survey sheds light on international genetic testing patterns in prostate cancer

Hannah Clarke
Data demonstrated wide variation in the proportion of patients recommended for testing and showed that barriers to testing remain.
Variants of unknown significance may adversely affect RARP outcomes
November 11th 2024

Variants of unknown significance may adversely affect RARP outcomes

Hannah Clarke
In total, 33.3% of patients with a VUS also had positive lymph node involvement and required adjuvant ADT compared with only 16.2% of patients who did not have a VUS.
Genetic testing in prostate cancer is increasing over time, data suggests
November 11th 2024

Genetic testing in prostate cancer is increasing over time, data suggests

Hannah Clarke
“It is critical that urologists understand when to order germline testing, are comfortable with actually ordering these tests, and integrate medical geneticists when appropriate," says Aditya Bagrodia, MD, FACS.
© 2024 MJH Life Sciences

All rights reserved.